Investigation of Anti-osteoporosis Mechanisms of Rehmanniae Radix Preparata Based on Network Pharmacology and Experimental Verification

Li Ou (✉ 23127438@qq.com)  
Shaanxi University of Chinese Medicine  
https://orcid.org/0000-0001-8767-1322

Wenqian Kang  
Shaanxi University of Chinese Medicine

Ziyi Liang  
Shaanxi University of Chinese Medicine

Feng Gao  
Shaanxi University of Chinese Medicine

Taiwei Dong  
Shaanxi University of Chinese Medicine

Peifeng Wei  
Shaanxi University of Chinese Medicine

Min Li  
Shaanxi University of Chinese Medicine

Research Article

Keywords: Rehmanniae Radix Preparata, network pharmacology, mechanism, osteoporosis, bone

DOI: https://doi.org/10.21203/rs.3.rs-773165/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

**Background:** *Rehmanniae Radix Preparata* (RRP) can effectively improve the symptoms of osteoporosis, but its molecular mechanism for treating osteoporosis is still unclear. The objective of this study is to investigate anti-osteoporosis mechanisms of *RRP* through network pharmacology.

**Methods:** The overlapping targets of RRP and osteoporosis were screened out using online platforms. A visual network diagram of PPI was constructed and analyzed by Cytoscape 3.7.2 software. Molecular docking was used to evaluate the binding activity of ligands and receptors, and some key genes were randomly verified through pharmacological experiments.

**Results:** According to topological analysis results, AKT1, MAPK1, ESR1, SRC, and MMP9 are key genes for RRP to treat osteoporosis, and they have high binding activity with stigmasterol and sitosterol. The main signal pathways of RRP in the treatment of osteoporosis, including Estrogen signaling pathway, HIF-1 signal pathway, MAPK signal pathway, PI3K-Akt signal pathway, etc. Results of animal experiments showed that RRP could significantly increase the expression levels of Akt1, ESR1 and SRC-1 mRNA in bone tissue to promote bone formation.

**Conclusion:** This study explained the coordination between multiple components and multiple targets of RRP in the treatment of osteoporosis, and provided new ideas and basis for its clinical application and experimental research.

Introduction

Osteoporosis is a common bone metabolic disease in middle-aged and elderly, which often leads to sprout, bone deformity and even fracture, and seriously affects the health and quality of life of middle-aged and elderly people [1, 2]. With the aging of the global population, its incidence is increasing year by year, so there is an urgent need to explore effective treatment methods [3, 4]. At present, the clinical treatment of osteoporosis is mainly through the application of three types of drugs: bone formation promoters, bone resorption inhibitors and bone mineral agents to improve the clinical symptoms of patients, but these treatment methods have certain limitations [5, 6]. Chinese herbal medicine has a long history of preventing and treating osteoporosis, with good curative effects and fewer side effects [7, 8]. *Rehmanniae Radix Preparata* (RRP) is a commonly used Chinese herbal medicine for the treatment of osteoporosis. Its main chemical components include sterol, styrene glycosides, amino acids, carbohydrates, etc., which can reduce bone loss and slow down aging [9, 10]. However, the material basis and molecular mechanism of RRP in the treatment of osteoporosis are still unclear.

Based on systems biology and bioinformatics, network pharmacology explores the interaction between biomolecules and targets in the body, so as to effectively predict the efficacy and mechanism of drugs [11]. This study integrated information such as active ingredients, drug targets and disease targets through network pharmacological methods to explore the material basis and mechanism of RRP in the treatment of osteoporosis.
This study explained the coordination between multiple components and multiple targets of RRP in the treatment of osteoporosis, and provided new ideas and basis for its clinical application and experimental research. First, overlapping targets of RRP and osteoporosis were screened out using online platforms. Next, a visual network diagram of PPI was constructed and analyzed by Cytoscape 3.7.2 software. Finally, molecular docking was used to evaluate the binding activity of ligands and receptors, and some key genes were randomly verified through pharmacological experiments. Network pharmacology research flow chart for RRP in the treatment of osteoporosis is shown in Fig. 1.

**Methods**

**Screening of anti-osteoporosis targets of RRP**

Osteoporosis-related targets were collected from online-accessible databases of DisGeNET (https://www.disgenet.org/), TTD (http://db.idrblab.net/ttd/) and Drukbank (https://www.drugbank.ca/) [12-14]. In addition, we used three online platforms: SEA (http://sea.bkslab.org), PharmMapper (http://www.lilab-ecust.cn/pharmmapper/) and SwissTargetPrediction (http://www.swisstargetprediction.ch/) to search for the target of RRP, and used UniProt database (https://www.Uniprot.org/) to standardize the gene ID [15-17]. Furthermore, all overlapping targets of RRP and osteoporosis were assayed by Venn diagrams to identify the targets for RRP-treated osteoporosis.

**Construction and analysis of protein interaction network**

The overlapping targets of RRP and osteoporosis were imported into STRING (https://string-db.org/) to obtain the protein-protein interaction (PPI) [18]. Then we used Cytoscape 3.7.2 software to construct a visual network diagram of PPI and further identified the targets for RRP-treated osteoporosis using cluster analysis [19].

**GO and pathway enrichment analysis for key targets**

The key genes were imported into several online biological information databases such as DAVID (version: 6.8) and STRING (version: 11.0), and GO and KEGG pathway enrichment analysis were performed [20,21].

**Molecular docking of RRP and key targets**

The 3D structure of the target protein was downloaded from PDB (https://www.rcsb.org/), and the water molecules and small molecule ligands of the target protein were removed using Pymol software [22]. Then we used AutoDock Tools software to prepare the hydrogenated protein and calculate the docking score.

**Establishment of the experimental model of osteoporosis**
Female SD rats weighing 200±20g were randomly divided into three groups: sham operation group, model group and RRP group, with 10 rats in each group. The experimental animals were purchased from Sichuan Chengdu Dashuo Experimental Animal Co., Ltd. (Chengdu, China), and the license number is SCXK 2019-028. Rats were kept in a well-ventilated environment with a room temperature of 22-25°C and relative humidity of 50%-60%. Animal experiments were carried out in accordance with the principles of the Care and Use of Laboratory Animal and the protocol was approved by the Animal Ethics Committee of Shaanxi University of Traditional Chinese Medicine (ethics approval number: AEC-19-002).

The rats in the model group and the RRP group underwent ovariectomy, while the ovaries in the sham operation group were not removed. After the operation, the vaginal secretions of the rats were collected, and the keratinized epithelial cells were not observed as a key indicator of successful ovariectomy. Both the sham operation group and the model group were intragastrically administered with distilled water, and the RRP group was intragastrically administered with a dose of 5.4 g/kg of RRP daily. The rats were dissected and their femurs were taken after 16 weeks.

**Bone density examination**

The rats were anesthetized by intraperitoneal injection of 3% sodium pentobarbital (1 ml/kg), and the right femur and the third lumbar vertebra were peeled off. A dual-energy X-ray bone densitometer (Lunar, United States) was used to detect the bone mineral density of the femur and lumbar spine of rats.

**Validation of key targets through qRT-PCR**

Three key targets were randomly verified by Real-Time quantitative reverse transcription (RT-PCR). Primers were designed and synthesized by the solid-phase phosphoramidite triester method, and the sequence of primer was as follows: AKT1 forward primer: 5’- GGCCCAGATGATCACCATCAC-3’; AKT1 reverse primer: 5’-CTATCGTC CAGCGCAGTCCA-3’; ESR1 forward primer: 5’- CCAACCAGTGCACCATTGAT-3’; ESR1 reverse primer: 5’-TTTGATCATGACGCGGCTTG-3-3’; SRC-1 forward primer: 5’- CAACCAGCAAGGCTGAGTCCA-3’; SRC-1 reverse primer: 5’- AGTACCTCCTGAGGGTTAGAG-3’. RNA of rats left femur were extracted with EasyPureTM RNA Kit (TransGen, China). TransScript rst-strand cDNA synthesis SuperMix kit (TransGen, China) was used for reverse transcription reaction. The program used consisted of a pre-denaturation step of 95°C for 3 min, 40 cycling of denaturation 94°C for 15 s, annealing temperature 50°C for 30 s, extension 72°C for 1 min, and a final extension step of 72°C for 5 min. The gene expression data was analyzed by using the 2^−ΔΔCT method.

**Statistical Analysis**

All statistical analyses were performed using SPSS19.0 software. All data were expressed as mean ± standard deviation ( ±s). One-way analysis of variance was used to analyze the data from multiple groups. P-Values of 0.05 or less were regarded as statistically significant.

**Results**
Active ingredients and targets of RRP in the treatment of osteoporosis

A total of 76 active ingredients of RRP were searched, and 2 active ingredients were screened based on oral bioavailability (OB)>30% and drug-likeness (DL)>0.18, including β-sitosterol (MOL000359) and stigmasterol (MOL000449). It was reported in the literature that 5-HMF could promote osteoblast production and might be one of the components of RRP in the treatment of osteoporosis. Therefore, although the DL value of 5-HMF (MOL000748) did not meet the standard, it was also included as an active ingredient (Table 1). We searched three online Platforms with the keyword “Osteoporosis” and identified 1179 osteoporosis-related targets. And we also obtained 428 RRP targets after removing duplicates. Finally, we found that there were a total of 118 overlapping targets for RRP and osteoporosis.

Table 1  Active ingredients of RRP
| Molecule ID  | Molecule Name | Structure | OB (%) | DL  |
|--------------|---------------|-----------|--------|-----|
| MOL000449    | stigmasterol  | ![](stigmasterol.png) | 43.83  | 0.76 |
| MOL000359    | sitosterol    | ![](sitosterol.png)  | 36.91  | 0.75 |
| MOL000748    | 5-HMF         | ![](5-HMF.png) | 45.07  | 0.02 |
Network construction and analysis

After the overlapping targets were uploaded to STRING (at 70% confidence), the PPI network with 98 nodes and 378 edges was constructed using Cytoscape 3.7.2 software (Fig. 2). In the generated network, nodes represented targets, and edges represented the interaction between targets. We used the Cytohub plug-in to analyze the network topology properties. The degree value of node reflected the importance of the node in the network. In the PPI network, the node color changed from yellow to green reflected the degree value changed from low to high. The top 10 genes were MAPK1, MAPK3, AKT1, MAPK8, ESR1, PTG stigmasterol, EGFR, FGF2, SRC, MMP9. Their degree values were more than two fold of the median degree of all nodes in the network [23].

The MCODE plug-in was used to decompose the PPI network, and seven closely connected sub-modules in the network were identified, including two 16-cores (the connectivity of each node in the module is at least 16), one 7-cores, one 6-cores, two 4-cores and one 3-cores (Fig. 3). This sub-module reflected the closely related proteins interaction that completed specific molecular functions. The genes in these sub-modules were closely related to the following molecular functions: enzyme binding, phosphotransferase activity, signaling receptor binding, protein kinase binding, protein tyrosine kinase activity, ion binding, steroid hormone receptor activity, phosphatidylinositol-4,5-bisphosphate 3-kinase activity, heme binding, G protein-coupled receptor activity. And these genes were involved in many important biological processes related to osteoporosis, such as regulation of cell population proliferation, positive regulation of nitrogen compound metabolic process, activation of protein kinase activity, positive regulation of reactive oxygen species metabolic process, regulation of phosphorylation, steroid metabolic process, vitamin D metabolic process, bone development, regulation of protein binding and G protein-coupled receptor signaling pathway.
**Enrichment analysis of key targets**

In the results of the enrichment of KEGG pathways, the pathways of basic biological processes were screened with false discovery rate (FDR) less than 0.01, and an enriched cluster containing 162 pathways was obtained (enrichment score = 2.12). According to the FDR value of these pathways, 10 pathways related to osteoporosis were screened out, including Estrogen signaling pathway, HIF-1 signaling pathway, VEGF signaling pathway, TNF signaling pathway, Ras signaling pathway, FoxO signaling pathway, MAPK signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation and Inflammatory mediator regulation of TRP channels (Table 2). Then we classified and visualized the pathways based on the number of key genes in these pathways (Fig. 4). The classification of these pathways belongs to endocrine system, signal transduction, development and regeneration and sensory system, which were the key target pathways of RRP to interfere with the biological process of osteoporosis.

**Table 2** KEGG signaling pathways regulated by important targets

| Category                        | Pathway                                      | Number of genes | Mapped targets | FDR       |
|---------------------------------|----------------------------------------------|-----------------|---------------|-----------|
| Endocrine system                | Estrogen signaling pathway                   | 99              | 12            | 8.91×10^{-7} |
| Signal transduction             | HIF-1 signaling pathway                      | 96              | 10            | 4.82×10^{-5} |
| Signal transduction             | VEGF signaling pathway signaling pathway     | 61              | 8             | 1.33×10^{-4} |
| Signal transduction             | TNF signaling pathway                        | 107             | 9             | 4.21×10^{-4} |
| Signal transduction             | Ras signaling pathway                        | 226             | 12            | 5.69×10^{-4} |
| Signal transduction             | FoxO signaling pathway                       | 134             | 9             | 0.001     |
| Signal transduction             | MAPK signaling pathway                       | 253             | 12            | 0.001     |
| Signal transduction             | PI3K-Akt signaling pathway                   | 345             | 14            | 0.001     |
| Development and regeneration    | Osteoclast differentiation                   | 131             | 8             | 0.004     |
| Sensory system                  | Inflammatory mediator regulation of TRP channels | 98          | 7             | 0.004     |

Note: KEGG: Kyoto Encyclopedia of Genes and Genomes; FDR: False discovery rate.

**Verification of molecular docking**

Molecular docking could effectively predict whether the ligand and the receptor could interact with each other through the complementarity of the spatial structure and the principle of energy minimization in the
region of the receptor active site [24,25]. The lower the docking score between the ligand and the receptor, the greater the docking activity of the two and the more stable the structure. The molecular docking results showed that the molecular docking score between the active ingredients of RRP and the key targets was all less than -4.2 kcal/mol, suggesting that these active ingredients have a certain affinity and binding activity with the key targets (Table 3). Docking score of the ligand and the receptor was less than -7.0 kcal/mol, which indicated that they had strong binding activity. A total of 14 binding conformations have docking scores less than -7.0. The top 9 binding relationships with the highest docking activity are AKT1-stigmasterol, AKT1-sitosterol, MAPK1-stigmasterol, MAPK1-sitosterol, ESR1-stigmasterol, SRC-stigmasterol, MMP9-stigmasterol, ESR1-sitosterol, MMP9-sitosterol (Fig. 5).

Table 3 Docking score of the active ingredients of RRP and key targets

| Molecule name | PDB ID | Docking score (kcal/mol) | stigmasterol | sitosterol | 5-HMF |
|---------------|--------|--------------------------|--------------|-----------|-------|
| MAPK1         | 4s33   | -9.7                     | -9.5         | -4.3      |
| MAPK3         | 6ges   | -5.3                     | -5.0         | -4.2      |
| AKT1          | 6hhf   | -10.3                    | -10          | -4.7      |
| MAPK8         | 3pze   | -8.2                     | -8.3         | -4.4      |
| ESR1          | 2iok   | -9.6                     | -8.7         | -4.3      |
| PTGS2         | 4cox   | -7.9                     | -8.1         | -5.0      |
| EGFR          | 5y9t   | -6.3                     | -5.9         | -3.8      |
| FGF2          | 4fgf   | -5.0                     | -4.6         | -3.2      |
| SRC           | 4u5j   | -9.1                     | -8.0         | -4.3      |
| MMP9          | 6esm   | -8.9                     | -8.6         | -5.6      |

Bone densitometry results

Compared with the sham operation group, the femur and vertebral bone mineral density of the model group were significantly decreased (P <0.01). Compared with the model control group, the RRP group could significantly increase the bone mineral density of the femur of ovariectomized rats (P <0.01), and could significantly increase the bone density of the vertebral body (P <0.05), as shown in Fig. 6-7.

Effect on AKT1, ESR1 and SRC-1 mRNA expression

The relative quantitative expression levels of AKT1, ESR1 and SRC mRNA were calculated by the $^{2-\Delta\Delta CT}$ method. The results showed that compared with the sham operation group, the expression levels of AKT1, ESR1 and SRC mRNA in the bone tissue of the model group decreased significantly (P<0.05). Compared with the model group, the expression of AKT1, ESR1 and SRC mRNA in the bone tissue of the
RRP group increased significantly (P<0.05). The results showed that RRP could increase the expression levels of AKT1, ESR1 and SRC mRNA in the bone tissue of osteoporotic rats (Fig. 8).

Discussion

The high morbidity and mortality of osteoporosis and osteoporotic fractures not only seriously affect the quality of life of the elderly, but also cause a huge economic and social health burden [26]. RRP can effectively prevent and treat osteoporosis [27], but the material basis and molecular mechanism of its treatment of osteoporosis are still unclear. A total of 76 active ingredients of RRP were searched, and 3 active ingredients were screened: β-sitosterol, stigmasterol and 5-HMF. After removing the duplication, we obtained 428 RRP targets and 1,179 targets related to osteoporosis, of which 118 overlapping targets were the common targets of RRP and osteoporosis. We used the Cytohub plug-in to analyze the PPI network topology properties. According to the node degree value, the top 10 genes are MAPK1, MAPK3, AKT1, MAPK8, ESR1, PTGS2, EGFR, FGF2, SRC, MMP9. Results of molecular docking showed that AKT1, MAPK1, ESR1, SRC, MMP9 and Stigmasterol had strong binding activity. AKT1, MAPK1, ESR1, MMP9 and Sitosterol also had high binding activity. The main signal pathways of RRP in the treatment of osteoporosis, including Estrogen signaling pathway, HIF-1 signal pathway, MAPK signal pathway, PI3K-Akt signal pathway, VEGF signal pathway, osteoclast differentiation of TRP channel and regulation of inflammatory mediators, etc. The classification of these pathways belongs to endocrine system, signal transduction, development and regeneration and sensory system, which were the key target pathways of RRP to interfere with the biological process of osteoporosis.

MAPK is the main carrier for signal transmission from the cell surface to the nucleus, mainly involved in the growth, differentiation and apoptosis caused by extracellular stimulation, and is a positive regulator of osteoblast differentiation and bone formation [28]. MAPK1, MAPK3 and MAPK8 are important members of the mitogen-activated protein kinase family. MAPK protein binds to the receptor complex, leading to inactivation of the cytosolic complex and degradation of β-catenin. The β-congenial protein can accumulate in the cytoplasm, and then transferred to the nucleus to promote the expression of specific genes in the bone, ultimately resulting in osteogenic differentiation to reduce and promote osteoblasts [29, 30]. Activation of the MAPK pathway increases the proliferation and migration of osteoblasts, which can promote bone healing. Inhibition of MAPK signaling reduces the expression of specific genes in mature osteoblasts [31, 32]. Estrogen is an important factor in increasing bone density and preventing bone loss after menopause. ESR1 is a nuclear biological macromolecule that mediates the biological effects of estrogen. Under the stimulation of EGF or IGF, the activated MAPK phosphorylates the serine of ESR1, allowing the receptor to bind to the specific coactivator of ESR1 to activate target genes [33].

When estrogen is insufficient, TNF-α promotes the proliferation and differentiation of osteoclast precursor cells and inhibits the formation of osteoblasts. Estrogen can also biphaseally activate nitric oxide synthase in endothelial cells through MAPK and PI3K/Akt pathways [34]. In osteoblasts and osteoclasts, estradiol rapidly activates MAPK, which may be involved in cell proliferation and anti-apoptotic effects to prevent osteoporosis [35]. VEGF is an important downstream gene of the HIF-1 signaling pathway, which
can promote the formation of osteoclasts and increase the activity of osteoclasts [36, 37]. The VEGF produced by mature osteoblasts is essential for the angiogenesis-osteogenesis coupling. VEGF can promote the production of osteochondral progenitor cells during bone repair and endochondral bone formation [38, 39]. PI3K/Akt signaling pathway is also involved in regulating the proliferation, differentiation and apoptosis of osteoclasts and osteoblasts [40, 41]. Studies have found that the lack of Akt1 in osteoclasts can lead to cellular dysfunction and impaired bone resorption [42, 43]. SRC-1 is an important nuclear receptor co-activator, which can enhance the effect of estrogen in many tissues and positively regulate the bone formation related to estrogen [44]. Experimental results showed that RRP could significantly increase the expression levels of Akt1, ESR1 and SRC-1 mRNA in bone tissue.

Conclusions

This study applied network pharmacology and molecular docking methods to study the material basis and potential mechanism of RRP in the treatment of osteoporosis. RRP interferes with the biological process of osteoporosis through the endocrine system, signal transduction, development and regeneration, and sensory system. The experimental animal study showed that RRP could significantly increase the expression levels of Akt1, ESR1 and SRC-1 mRNA in bone tissue to promote bone formation. This study explained the coordination between multiple components and multiple targets of RRP in the treatment of osteoporosis, and provided new ideas and basis for its clinical application and experimental research.

Abbreviations

RRP: *Rehmanniae Radix Preparata*; PPI: Protein-protein interaction; GO: Gene ontology; KEGG: Kyoto encyclopedia of genes and genomes; OB: Oral bioavailability; DL: Drug-likeness; RT-PCR: Real-Time quantitative reverse transcription; FDR: False discovery rate

Declarations

Acknowledgments

All authors would like to thank to the Laboratory of Clinical Chinese Pharmacy.

Authors’ contributions

O.L, L.ZY, K.WQ designed the study, analyzed the experiments, and wrote the paper. G.F, D.TW, W.PF, and L.M carried out the data collection and data analysis and revised the paper. The authors read and approved the final manuscript.

Funding
This study was supported by National Natural Science Foundation of China (No. 81903877); Shaanxi Provincial Department of Science and Technology Project (No. 2020JM-589); Shaanxi University of Traditional Chinese Medicine Innovation Team Project (No. 2019-QN02).

Availability of data and materials

All the data will be available upon motivated request to the corresponding author of the present paper.

Ethical approval and consent to participate

This study was conducted in agreement with the Declaration of Helsinki and its later amendments or comparable ethical standards and had been approved by the ethics board of Shaanxi University of Traditional Chinese Medicine (No: AEC-19-002).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

College of Pharmacy, Shaanxi University of Chinese Medicine, Xian yang 712046, China.

References

1. Gates BJ, Das S. Management of osteoporosis in elderly men. Maturitas. 2011;69(2):113–9. https://doi.org/10.1016/j.maturitas.2011.03.009.

2. Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25(5):1439–43. https://doi.org/10.1007/s00198-014-2655-z.

3. Ma YZ, Wang YP, Liu Q, Li CL, Ma X, Wang YJ, et al. Guidelines for diagnosis and treatment of senile osteoporosis in China(2018). Chinese Journal of Practical Internal Medicine. 2019;39(1):38–61. https://doi.org/10.19538/j.nk2019010109.

4. Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q, et al. The prevalence of osteoporosis in China, a nationwide, multicenter DXA survey. J Bone Miner Res. 2019;34(10):1789–97. https://doi.org/10.1002/jbmr.3757.

5. Cagnacci A, Venier M. The controversial history of hormone replacement therapy. Medicina. 2019;55(9). https://doi.org/10.3390/medicina55090602.

6. Canalis E. New treatment modalities in osteoporosis. Endocr Pract. 2010;16(5):855–63. https://doi.org/10.4158/ep10048.Ra.
7. Zhang YF, An JW, Gong YB. D.Y. C. Research progress on the prevention and treatment of primary osteoporosis by Chinese medicine. Chin J Osteoparos. 2019;25(4):554–8. https://doi.org/10.3969/j.issn.1006-7108.2019.04.026.

8. Wu D, Lin YX, Li JJ, Wu YT, Fang ZH. Clinical research progress of Chinese medicine in the treatment of osteoporosis in recent ten years. Clin J Tradit Chin Med. 2019;31(11):2038–41. https://doi.org/10.16448/j.cjtcm.2019.0592.

9. Shen HD, Fang JJ, Guo PC, Ding TM, Liu JF, Ding XP. Study of anti-oxidants of Rehmanniae Radix and Rehmannia Radix Praeparata by HPLC-UV-DPPH method. Chin Tradit Herb Drugs. 2018;49(3):582–8. https://doi.org/10.7501/j.issn.0253-2670.2018.03.012.

10. Hu GC, Zhang MJ, Zhan Q, Shen QR. A summary of modern research on the treatment of primary osteoporosis with Rehmannia glutinosa. Zhejiang J Tradit Chin Med. 2019;54(3):232–3. https://doi.org/10.13633/j.cnki.zjtcm.2019.03.056.

11. Luo TT, Lu Y, Yan SK, Xiao X, Rong XL, Guo J. Network pharmacology in research of Chinese medicine formula: methodology, application and prospective. Chin J Integr Med. 2020;26(1):72–80. https://doi.org/10.1007/s11655-019-3064-0.

12. Piñero J, Bravo À, Queralt-Rosinach N, Gutiérrez-Sacristán A, Deu-Pons J, Centeno E, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2017;45(D1):D833-d9. https://doi.org/10.1093/nar/gkw943.

13. Wang Y, Zhang S, Li F, Zhou Y, Zhang Y, Wang Z, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020;48(D1):D1031-d41. https://doi.org/10.1093/nar/gkz981.

14. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-d82. https://doi.org/10.1093/nar/gkx1037.

15. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol. 2007;25(2):197–206. https://doi.org/10.1038/nbt1284.

16. Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45(W1):W356-w60. https://doi.org/10.1093/nar/gkx374.

17. Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357-w64. https://doi.org/10.1093/nar/gkx382.

18. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-d13. https://doi.org/10.1093/nar/gky1131.
19. Doncheva NT, Morris JH, Gorodkin J, Jensen LJ. Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data. J Proteome Res. 2019;18(2):623–32. https://doi.org/10.1021/acs.jproteome.8b00702.

20. Jiao X, Sherman BT, Huang da W, Stephens R, Baseler MW, Lane HC, et al. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics. 2012;28(13):1805–6. https://doi.org/10.1093/bioinformatics/bts251.

21. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362-d8. https://doi.org/10.1093/nar/gkw937.

22. Burley SK, Berman HM, Kleywegt GJ, Markley JL, Nakamura H, Velankar S. Protein data bank (PDB): the single global macromolecular structure archive. Methods Mol Biol. 2017;1607627-41. https://doi.org/10.1007/978-1-4939-7000-1_26.

23. Zhang Y, Li Y, Mao X, Yan C, Guo X, Guo Q, et al. Thyroid hormone synthesis: a potential target of a Chinese herbal formula Haizao Yuhu Decoction acting on iodine-deficient goiter. Oncotarget. 2016;7(32):51699–712. https://doi.org/10.18632/oncotarget.10329.

24. Li J, Fu A, Zhang L. An overview of scoring functions used for protein-ligand interactions in molecular docking. Interdiscip Sci. 2019;11(2):320–8. https://doi.org/10.1007/s12539-019-00327-w.

25. Tanchuk VY, Tanin VO, Vovk AI, Poda G. A new, improved hybrid scoring function for molecular docking and scoring based on AutoDock and AutoDock Vina. Chem Biol Drug Des. 2016;87(4):618–25. https://doi.org/10.1111/cbd.12697.

26. Coughlan T, Dockery F. Osteoporosis and fracture risk in older people. Clin Med (Lond). 2014;14(2):187 – 91. https://doi.org/10.7861/clinmedicine.14-2-187.

27. Tao Y, Shen T, Ma H. Comparison on efficacy of Rehmanniae Radix Praeparata and its paired medicines for treatment of diabetic osteoporosis in rats. Chin J Exp Tradit Med Form. 2012;18(8):249–51. https://doi.org/10.13422/j.cnki.syfjx.2012.08.084.

28. Ding Y, Cui Y, Zhang LQ. Signal pathways regulating bone formation. Chin J Biochem Mol Biol. 2021;37(4):1–12. https://doi.org/10.13865/j.cnki.cjbmb.2021.01.1392.

29. Ma JG, Gao ZM, Jin L. MiR-367 inhibits osteoblast proliferation through Wnt/β-catenin pathway. J Pract Orthop. 2020;26(1):34 – 9. https://doi.org/10.13795/j.cnki.sgkz.2020.01.009.

30. Yao H, Yao Z, Zhang S, Zhang W, Zhou W. Upregulation of SIRT1 inhibits H2O2–induced osteoblast apoptosis via FoxO1/β–catenin pathway. Mol Med Rep. 2018;17(5):6681–90. https://doi.org/10.3892/mmr.2018.8657.

31. Zhang Y, Gu X, Li D, Cai L, Xu Q. METTL3 Regulates Osteoblast Differentiation and Inflammatory Response via Smad Signaling and MAPK Signaling. Int J Mol Sci. 2019;21(1). https://doi.org/10.3390/ijms21010199.

32. Guo C, Yang RJ, Jang K, Zhou XL, Liu YZ. Protective Effects of Pretreatment with Quercetin Against Lipopolysaccharide-Induced Apoptosis and the Inhibition of Osteoblast Differentiation via the MAPK
and Wnt/β-Catenin Pathways in MC3T3-E1 Cells. Cell Physiol Biochem. 2017;43(4):1547–61. https://doi.org/10.1159/000481978.

33. Chen GH, Zhang XL, Chen H, Lin H, Wu HJ, Lin H, et al. miR-22 represses osteoblast viability with ESR1 presenting a direct target and indirectly inactivating p38 MAPK/JNK signaling. J Gene Med. 2020;22(6):e3174. https://doi.org/10.1002/jgm.3174.

34. Chen C, Yin YY, Wu XF, Wu RR, Xu YY. Advance in researches on role of MAPK and PI3K/AKT pathways in ROS-induced activation of nuclear factor erythroid 2-related factor 2. Chin J Public Health. 2016;32(6):870–3. https://doi.org/10.11847/zgggws2016-32-06-41.

35. Liu M, Xie WW, Zheng W, Yin DY, Luo R, Guo FJ. Targeted binding of estradiol with ESR1 promotes proliferation of human chondrocytes in vitro by inhibiting activation of ERK signaling pathway. J South Med Univ. 2019;39(2):134–43. https://doi.org/10.12122/j.issn.1673-4254.2019.09.02.

36. Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T, Kanagawa H, et al. HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci U S A. 2013;110(41):16568–73. https://doi.org/10.1073/pnas.1308755110.

37. Hu K, Olsen BR. Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair. J Clin Invest. 2016;126(2):509–26. https://doi.org/10.1172/jci82585.

38. Jafri MA, Kalamegam G, Abbas M, Al-Kaff M, Ahmed F, Bakhashab S, et al. Deciphering the Association of Cytokines, Chemokines, and Growth Factors in Chondrogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells Using an ex vivo Osteochondral Culture System. Front Cell Dev Biol. 2019;7380. https://doi.org/10.3389/fcell.2019.00380.

39. Duan X, Bradbury SR, Olsen BR, Berendsen AD. VEGF stimulates intramembranous bone formation during craniofacial skeletal development. Matrix Biol. 2016;52-54127-40. https://doi.org/10.1016/j.matbio.2016.02.005.

40. Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee SY, et al. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J Immunol. 2012;188(1):163–9. https://doi.org/10.4049/jimmunol.1101254.

41. Zou W, Yang S, Zhang T, Sun H, Wang Y, Xue H, et al. Hypoxia enhances glucocorticoid-induced apoptosis and cell cycle arrest via the PI3K/Akt signaling pathway in osteoblastic cells. J Bone Miner Metab. 2015;33(6):615–24. https://doi.org/10.1007/s00774-014-0627-1.

42. Jiang P, Song KG. Research progress on osteoclast and its differentiation regulation mechanism. Chin J Bone Joint. 2017;6(3):223–7. https://doi.org/10.3969/j.issn.2095-252X.2017.03.013.

43. Choi YH, Choi HJ, Lee KY, Oh JW. Akt1 regulates phosphorylation and osteogenic activity of Dlx3. Biochem Biophys Res Commun. 2012;425(4):800–5. https://doi.org/10.1016/j.bbrc.2012.07.155.

44. Watters RJ, Hartmaier RJ, Osmanbeyoglu HU, Gillihan RM, Rae JM, Liao L, et al. Steroid receptor coactivator-1 can regulate osteoblastogenesis independently of estrogen. Mol Cell Endocrinol. 2017;44821-7. https://doi.org/10.1016/j.mce.2017.03.005.

Figures
Figure 1

Network pharmacology research flow chart
Figure 2

PPI network. PPI: Protein-protein interaction
Figure 3
Densely linked modules included in target network of RRP

Figure 4
Bubble diagram of top 10 KEGG enrichment pathways
**Figure 5**

Molecular docking model diagram
Figure 6

X-ray image of rat. A) Sham operation group. B) Model group. C) RRP group
**Figure 7**

Effect on bone mineral density. Compared with the sham operation group, ##P<0.01; Compared with the model group, **P<0.01, *P<0.05

**Figure 8**

Effect on AKT1, ESR1 and SRC mRNA expression. Compared with the sham operation group, #P<0.05; Compared with the model group, *P<0.05